EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pt‐TiO 2 mesoporous nanosystem co‐delivering phlorizin enables synergistic sonodynamic‐chemoimmunotherapy for hepatocellular carcinoma via directly targeting DDX5 and metabolic reprogramming modulation

Kairui Liu, Bo Zhang, Yue Wan, Zhiru Yang, Abdusami Abdurahman, Mengxin He, Shengtao Hu, Yi Zhang, Xiaoke Li, Jin Chang, Jun Kang, Liren Liu und 2 weitere

BMEMat · 2026-09 · 4 (3)

DOI: 10.1002/bmm2.70075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMEMat, online erschienen am 11.03.2026. Verfasst von Kairui Liu und 13 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC), ranking as the third leading cause of cancer‐related mortality globally, continues to pose significant therapeutic challenges. Here, we developed an innovative nanosystem, Phl@PT, based on Pt‐TiO 2 nanoparticles for the co‐delivery of Phlorizin, presenting a novel approach for HCC treatment through sonodynamic therapy (SDT). Phl@PT demonstrated remarkable efficacy in inducing mitochondrial membrane potential collapse and cristae damage in vitro. Transcriptomic sequencing analysis revealed that Phl@PT treatment led to the downregulation of key genes: CLDN6 , involved in the cell adhesion molecules pathway, and BCKDHB and SUCLG2 , associated with propanoate metabolism. Through a comprehensive target fishing strategy combined with Bio‐Layer Interferometry analysis, we identified DDX5, a DEAD‐box RNA helicase, as a novel target protein of Phlorizin, which plays a crucial role in tumor progression and prognosis. In vivo studies demonstrated that US‐activated Phl@PT not only effectively inhibited HCC growth in murine models but also activated CD8 + /CD4 + T cells, promoted dendritic cell maturation, and enhanced the expression of key immune cytokines including TNF‐α, IL‐12, and IFN‐γ, thereby establishing a robust immunotherapeutic response. Collectively, our findings demonstrate that the Pt‐TiO 2 mesoporous nanoagent co‐delivering phlorizin represents a promising therapeutic platform for HCC treatment through synergistic sonodynamic‐chemo‐immunotherapy.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, K., Zhang, B., Wan, Y., Yang, Z., Abdurahman, A., He, M., Hu, S., Zhang, Y., Li, X., Chang, J., Kang, J., Liu, L., Liu, W., & Li, S. (2026). Pt‐TiO 2 mesoporous nanosystem co‐delivering phlorizin enables synergistic sonodynamic‐chemoimmunotherapy for hepatocellular carcinoma via directly targeting DDX5 and metabolic reprogramming modulation. BMEMat, 4(3). https://doi.org/10.1002/bmm2.70075

Vancouver

Liu K, Zhang B, Wan Y, Yang Z, Abdurahman A, He M, et al. Pt‐TiO 2 mesoporous nanosystem co‐delivering phlorizin enables synergistic sonodynamic‐chemoimmunotherapy for hepatocellular carcinoma via directly targeting DDX5 and metabolic reprogramming modulation. BMEMat. 2026;4(3). doi:10.1002/bmm2.70075

BibTeX
@article{Liu2026,
  author = {Liu, Kairui and Zhang, Bo and Wan, Yue and Yang, Zhiru and Abdurahman, Abdusami and He, Mengxin and Hu, Shengtao and Zhang, Yi and Li, Xiaoke and Chang, Jin and Kang, Jun and Liu, Liren and Liu, Wanghua and Li, Shao},
  title = {Pt‐TiO 2 mesoporous nanosystem co‐delivering phlorizin enables synergistic sonodynamic‐chemoimmunotherapy for hepatocellular carcinoma via directly targeting DDX5 and metabolic reprogramming modulation},
  journal = {BMEMat},
  year = {2026},
  volume = {4},
  number = {3},
  doi = {10.1002/bmm2.70075}
}
Kostenlos starten →